Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. - Wikidata - wikimedia - TriplyDB

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

http://www.wikidata.org/entity/Q35048395

about

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies Emerging Therapies for Rheumatoid Arthritis [Success for a new generation of disease-modifying antirheumatic drugs : The Janus kinase inhibitor baricitinib in rheumatoid arthritis].A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study.Trisomy 21 consistently activates the interferon response.Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.Novel treatment options for juvenile idiopathic arthritis.Efficacy of baricitinib in the treatment of rheumatoid arthritis.Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Developing Treatments for Chronic Kidney Disease in the 21st Century.Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.A novel therapeutic paradigm for patients with extensive alopecia areata.Baricitinib for the treatment of rheumatoid arthritis.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.Baricitinib: First Global Approval.Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication.Decernotinib: A Next-Generation Jakinib.Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications.The Future of Atopic Dermatitis Treatment.Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.Investigational drugs in systemic vasculitis.Chemical JAK inhibitors for the treatment of rheumatoid arthritis.Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?[Psoriatic arthritis : Drugs of the (near) future].

P2860

Q26775111-E1515DD6-8CC4-4E94-8ED3-B51FB07EE3B0 Q26786973-3B84D6A0-55EA-4DDE-8A9F-D93147E70BEC Q28078943-F1BD5353-88E9-4E38-AD9B-86E30A5DF26B Q30313219-CEA70F12-6EB2-4B14-8589-6475B5F2FF72 Q34533371-5ED30A86-5BA0-4091-9F61-466D9503E1B7 Q34533379-E1DC0E3B-508C-47E3-893A-A945FB1CD986 Q36912333-BA8F298D-DCF4-4792-BBCB-D6D5C3920DCC Q37235217-D63CCA3D-567D-4B3C-8589-01FC84096688 Q37604501-4547A54B-52B7-4C26-8A96-0B9796D88634 Q37696609-F02FA198-2FD4-41F6-B192-D12B86703B6D Q38372369-8E947B7F-4285-4EC6-816C-8B665487E07A Q38543700-73084BD9-3438-4105-8E80-7C2F1E66D32C Q38570721-D308DA49-7F95-412E-A78D-DC22D4E742FA Q38652849-CD20EEB7-23CA-4EF5-AB56-C473E3C0AE1C Q38708002-8D9C3A62-F37D-4CAE-88E7-94911ADFCFA0 Q38751230-2B9B713A-1532-42F2-8D8C-0BADD70B7E01 Q38781550-35D17D75-A36E-43D7-81C2-2F13B919B9C5 Q38821079-990DA475-21B6-48B4-B77E-021F73777FD0 Q38831003-9EB051F6-B18B-4789-B3E8-48385A4A1491 Q38840787-E2A2C914-A210-461F-8014-F6EE9474FDA8 Q38883893-F93708EB-4231-4E7E-83DC-570E8C0343D8 Q38932097-06519C42-C351-4807-82C5-492B00435FFA Q38941577-FAC1D881-714D-4000-8593-F22F5D732FB2 Q39020448-82AA844B-61D6-4D95-9BD4-D5F6EA1105B9 Q39068415-1EDA60D0-3CD7-4AD9-A98D-DE151FA7F7FF Q39177156-B4709EBC-4390-4322-95BF-B3B1D7603CD8 Q40504454-C052ACE8-4CCD-4810-AC63-75DE2C32DF83 Q42356300-CE6F17ED-FAB5-471A-9E55-551B9DEA7841 Q42394345-318E948A-4E89-4118-B7B7-A0375F8AD613 Q44067316-38286D45-FAB3-4347-8EB2-1C09CD7759D1 Q47103417-C77D1992-43B1-4FCC-B7E2-D49BD59404B4 Q47132835-60B48653-0CFE-426F-A02C-B96C5C5B2515 Q47602482-8D369F17-E721-4521-B497-E3A7F1A4390B Q47800990-5BCE84DA-3F16-4DCE-B9C7-8B449EE1210A Q47880524-73FDB77C-656C-4F46-871F-8C3C0291CFD8 Q49792187-CD05FBBF-352D-417F-9601-B10873DA25C5 Q51834131-D612DDC4-8EAF-4541-A952-69A9DE4EFCA8 Q54172510-335E342F-2FFC-4F47-A5DF-1A4D0AD2ED22 Q54977224-E714BBE4-41BE-48ED-8D7B-1850AD74E1E7 Q54998108-3AB3A386-3F68-454B-A3DC-9F18525B4BC5

P2860

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

http://www.wikidata.org/entity/Q35048395

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety and efficacy of baricit ...... uate response to methotrexate.

@en

type

label

Safety and efficacy of baricit ...... uate response to methotrexate.

@en

prefLabel

Safety and efficacy of baricit ...... uate response to methotrexate.

@en

P1433

Q35048395-5E0309F1-564D-417A-A1CB-D221533663A4

P1476

Q35048395-F88A2784-BDC9-4B65-BABF-A8496CAB7EC4

P2093

Q35048395-2C4DDA49-C380-4E9F-B349-050E2A103850

Q35048395-440EDD3B-0824-403B-9126-B2AFD37DADDD

Q35048395-51BF5A71-AA0F-4543-9F06-5B19E29C810F

Q35048395-629BA0AC-F905-488D-BEB9-36A1624B7EC9

Q35048395-66C7AE89-3C85-4D1A-8192-F213B03E2F8D

Q35048395-7EC2AB17-F640-4E91-B541-B0CA02BEC0E4

Q35048395-94D03BE1-B976-4CE8-97BA-98837F541507

Q35048395-A1B9A091-D0CA-4438-8342-FB450FF7A20E

Q35048395-B6DC6CF5-8345-4020-B2FF-715328B98734

Q35048395-D36A48B3-65C7-4CF3-8FEE-5DA8657CA521

P2860

Q35048395-3BDC1C4D-F28A-4B9F-B3B3-BA7ADC7AA1E1

Q35048395-6625528C-2D1E-4FFC-8AE6-6AC0ED5F0B97

Q35048395-6B65C30E-69CA-4CB3-9158-825C0ED04875

Q35048395-806A16FE-F4FE-4488-AD2C-028A0ABE5F45

Q35048395-A63BCE0D-73F1-467B-A536-9E2A894050A7

Q35048395-B89438AB-C11B-44A0-B864-DEF41E0BFCDF

Q35048395-BD92C382-4294-48E1-9B3A-18224AD52D72

Q35048395-C1791920-9311-46A6-A010-6F8D12CD2113

Q35048395-C99E37B5-719A-4ED3-85CE-BCD89B3AD6F7

Q35048395-CD9A24D3-845B-42CB-B1CD-60B14DA5E47A

P304

Q35048395-FCDEC117-CA6B-4321-A1BC-779456353286

P31

Q35048395-4F086783-11E2-4C71-8D25-2747C1B0EED4

P356

Q35048395-49A7CD64-1C9D-4451-8C83-C1CB49522885

P407

Q35048395-713BD01F-FDAF-4437-843D-AC3036CB3C72

P433

Q35048395-0247A76D-9873-4047-A5FD-DF4BB7AF1A73

P478

Q35048395-4E2F773B-3D72-4E74-959D-96BE399AE4E6

P577

Q35048395-B0779342-E3F2-4395-A49C-C57D776EA86E

P5875

Q35048395-95909DD4-0925-40F2-96A5-073F5ABAFD8C

P698

Q35048395-0B6DB2B6-47EA-40AF-BDFF-C3E7928C1C8F

P932

Q35048395-7ACE8457-4EEE-4CB1-A4F6-7043D72892B4

P356

ANNRHEUMDIS-2014-206478

P1433

Annals of the Rheumatic Diseases

P1476

Safety and efficacy of baricit ...... uate response to methotrexate.

@en

P2093

Chin H Lee

http://www.w3.org/2001/XMLSchema#string

Douglas E Schlichting

http://www.w3.org/2001/XMLSchema#string

Edit Drescher

http://www.w3.org/2001/XMLSchema#string

Edward C Keystone

http://www.w3.org/2001/XMLSchema#string

Mark C Genovese

http://www.w3.org/2001/XMLSchema#string

Monica E Luchi

http://www.w3.org/2001/XMLSchema#string

Peter C Taylor

http://www.w3.org/2001/XMLSchema#string

Pierre-Yves Berclaz

http://www.w3.org/2001/XMLSchema#string

Rosanne K Fidelus-Gort

http://www.w3.org/2001/XMLSchema#string

Scott D Beattie

http://www.w3.org/2001/XMLSchema#string

P2860

Janus kinase inhibitors in autoimmune diseases

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Jaks and STATs: biological implications

Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.

The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

JAKs and STATs in immunity, immunodeficiency, and cancer.

The Disease Activity Score and the EULAR response criteria.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

P304

333-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2014-206478

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268881375

http://www.w3.org/2001/XMLSchema#string

P698

25431052

http://www.w3.org/2001/XMLSchema#string

P932

4316868

http://www.w3.org/2001/XMLSchema#string